These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 583232)

  • 21. Pharmacokinetics of PFA (trisodium phosphonoformate) after i.v. and p.o. administration to beagle dogs and rabbits.
    Ritschel WA; Grummich KW; Hussain SA
    Methods Find Exp Clin Pharmacol; 1985 Jan; 7(1):41-8. PubMed ID: 3157841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hexobarbital pharmacokinetics in rats after ligation of the common bile duct.
    Drew R; Priestly BG; O'Reilly WJ
    J Pharmacol Exp Ther; 1977 Jun; 201(3):534-40. PubMed ID: 864592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circadian rhythms in drug action and drug metabolism in the mouse.
    Holcslaw TL; Miya TS; Bousquet WS
    J Pharmacol Exp Ther; 1975 Nov; 195(2):320-32. PubMed ID: 1185601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronopharmacokinetics of ethanol. I. Review of the literature and theoretical considerations.
    Sturtevant FM
    Chronobiologia; 1976; 3(3):237-62. PubMed ID: 797559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of simultaneously administered hexobarbital and heptabarbital in rats: an alternative approach to metabolic correlation studies.
    van der Graaff M; Vermeulen NP; Langendijk PN; Breimer DD
    J Pharmacol Exp Ther; 1983 Jun; 225(3):747-51. PubMed ID: 6134816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic analysis of ampicillin concentration in neonates: comparison of two pharmacokinetic models and of two numerical methods.
    Hermans J; Driessen O; Sorgedrager N; Spoor M
    Arzneimittelforschung; 1975 Jun; 25(6):947-9. PubMed ID: 1174334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin.
    Jolling K; Perez Ruixo JJ; Hemeryck A; Vermeulen A; Greway T
    Eur J Pharm Sci; 2005 Apr; 24(5):465-75. PubMed ID: 15784336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A simple pharmacokinetics subroutine for modeling double peak phenomenon.
    Mirfazaelian A; Mahmoudian M
    Biopharm Drug Dispos; 2006 Apr; 27(3):119-24. PubMed ID: 16400712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Studies on the pharmacokinetics of amoxicillin after intravenous, intramuscular and oral administration (author's transl)].
    Dalhoff A; Koeppe P; von Kobyletzki D
    Arzneimittelforschung; 1981; 31(7):1148-57. PubMed ID: 7196765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery.
    Breimer DD; Zilly W; Richter E
    Clin Pharmacol Ther; 1975 Oct; 18(4):433-40. PubMed ID: 1164825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements.
    Hempel G; Karlsson MO; de Alwis DP; Toublanc N; McNay J; Schaefer HG
    Clin Pharmacol Ther; 1998 Dec; 64(6):622-35. PubMed ID: 9871427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of compartment models in the pharmacokinetics].
    Weiss M; Förster W
    Z Gesamte Inn Med; 1976 Sep; 31(17):673-9. PubMed ID: 997662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults.
    Park K; Kim YS; Kwon KI; Park MS; Lee YJ; Kim KH
    Clin Ther; 2007 Jan; 29(1):154-62. PubMed ID: 17379055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmocokinetics of hexobarbital in man after intravenous infusion.
    Breimer DD; Honhoff C; Zilly W; Richter E; van Rossum JM
    J Pharmacokinet Biopharm; 1975 Feb; 3(1):1-11. PubMed ID: 1127574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of corticosteroid on hexobarbital and tolbutamide disposition.
    Breimer DD; Zilly W; Richter E
    Clin Pharmacol Ther; 1978 Aug; 24(2):208-12. PubMed ID: 679598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disposition of hexobarbital: 15 years of an intriguing model substrate.
    van der Graaff M; Vermeulen NP; Breimer DD
    Drug Metab Rev; 1988; 19(2):109-64. PubMed ID: 3069420
    [No Abstract]   [Full Text] [Related]  

  • 38. [Dynamics of pulse frequency changes in dependence on time and exercise (author's transl)].
    Simáĉek I; Kolesár J
    Cas Lek Cesk; 1979 Apr; 118(14):419-21. PubMed ID: 455357
    [No Abstract]   [Full Text] [Related]  

  • 39. Sensitivity analysis of pharmacokinetic parameters in one-compartment models.
    Wu G
    Pharmacol Res; 2000 Apr; 41(4):445-53. PubMed ID: 10704269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid analysis of hexobarbital and its main metabolites in mice by high-performance liquid chromatography.
    Böcker R
    J Chromatogr; 1982 Mar; 228():350-4. PubMed ID: 7076760
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.